# CRISPR Therapeutics (CRSP) — Earnings

CRSP · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/crsp/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q3 2025 |
| Period end | Sep 30, 2025 |
| EPS actual | −$1.17 |
| EPS estimate | −$1.26 |
| EPS surprise | +7.48% |
| Revenue surprise | −90.25% |
| Revenue | $889,000.00 |
| Revenue estimate | $9.1M |
| Reported | Nov 10, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1674416/000119312525273337/crsp-20250930.htm) |

The latest quarter in CRISPR Therapeutics' table is Q3 2025, reported on November 10, 2025. The company posted a loss of $1.17 per share, narrower than the estimated loss of $1.26, a 7.48% beat. Revenue was $889,000, 90.25% below the $9.1 million consensus. A year earlier, Q3 2024 showed a loss of $1.01 per share on revenue of $602,000.

Losses dominate the record, with 18 of the 20 quarters shown in the red. The two profitable quarters, Q2 2021 at $9.44 per share and Q4 2023 at $1.10, came with revenue of $900.7 million and $201.2 million. In 13 of the 20 quarters revenue was below $1 million. Full-year results were EPS of $4.42 in 2021, then losses of $8.37 per share in 2022, $1.96 in 2023 and $4.37 in 2024. The first three quarters of 2025 add up to a loss of $5.15 per share. CRISPR beat the EPS estimate in 11 of 20 quarters, but revenue topped the consensus only six times.

The table has no rows after Q3 2025. Past fourth-quarter results were reported between February 11 and February 21. Newer reports will show whether revenue moves beyond the sub-$1 million level of 2025.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q3 2025 | Nov 10, 2025 | −$1.26 | −$1.17 | 7.48% | $9.1M | $889,000.00 |
| Q2 2025 | Aug 4, 2025 | −$1.40 | −$2.40 | -71.25% | $6.1M | $892,000.00 |
| Q1 2025 | May 6, 2025 | −$1.24 | −$1.58 | -27.05% | $6.3M | $865,000.00 |
| Q4 2024 | Feb 11, 2025 | −$1.20 | −$0.44 | 63.35% | $8.1M | $35.7M |
| Q3 2024 | Nov 5, 2024 | −$1.41 | −$1.01 | 28.29% | $6.5M | $602,000.00 |
| Q2 2024 | Aug 5, 2024 | −$1.43 | −$1.49 | -4.38% | $12.1M | $517,000.00 |
| Q1 2024 | May 8, 2024 | −$1.36 | −$1.43 | -5.09% | $24.3M | $504,000.00 |
| Q4 2023 | Feb 21, 2024 | $0.07 | $1.10 | 1559.13% | $140.9M | $201.2M |
| Q3 2023 | Nov 6, 2023 | −$1.99 | −$1.41 | 29.12% | $11.9M | — |
| Q2 2023 | Aug 7, 2023 | −$2.13 | −$0.98 | 53.93% | $1.8M | $70.0M |
| Q1 2023 | May 8, 2023 | −$1.74 | −$0.67 | 61.52% | $25.8M | $100.0M |
| Q4 2022 | Feb 21, 2023 | −$2.25 | −$1.41 | 37.34% | $7.1M | $6,000.00 |
| Q3 2022 | Nov 1, 2022 | −$2.28 | −$2.24 | 1.66% | $1.8M | $94,000.00 |
| Q2 2022 | Aug 8, 2022 | −$2.22 | −$2.40 | -8.27% | $2.2M | $158,000.00 |
| Q1 2022 | May 9, 2022 | −$1.94 | −$2.32 | -19.64% | $2.8M | $940,000.00 |
| Q4 2021 | Feb 15, 2022 | −$1.76 | −$1.84 | -4.30% | $2.2M | $12.9M |
| Q3 2021 | Nov 3, 2021 | −$1.75 | −$1.67 | 4.72% | $1.2M | $824,000.00 |
| Q2 2021 | Jul 29, 2021 | $3.52 | $9.44 | 167.99% | $900.2M | $900.7M |
| Q1 2021 | Apr 27, 2021 | −$1.47 | −$1.51 | -2.53% | $1.4M | $539,000.00 |
| Q4 2020 | Feb 16, 2021 | −$1.27 | −$1.50 | -17.82% | $2.2M | $370,000.00 |

## Frequently Asked Questions

### When did CRISPR Therapeutics (CRSP) last report earnings?

CRISPR Therapeutics last reported on Nov 10, 2025, covering fiscal Q3 2025.

### Did CRSP beat earnings estimates?

Yes. CRISPR Therapeutics reported EPS of −$1.17 for Q3 2025 against a −$1.26 estimate — a 7.48% beat.

### How much revenue did CRSP report last quarter?

CRISPR Therapeutics reported $889,000.00 in revenue for Q3 2025, against a consensus estimate of $9.1M.

## Similar Stocks

- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [NTLA](https://www.lighthorse.io/tickers/ntla) — Intellia Therapeutics, Inc. - Common Stock
- [KALA](https://www.lighthorse.io/tickers/kala) — KALA BIO, Inc. - Common Stock
- [BEAM](https://www.lighthorse.io/tickers/beam) — Beam Therapeutics Inc. - Common Stock
- [ALLO](https://www.lighthorse.io/tickers/allo) — Allogene Therapeutics, Inc. - Common Stock
- [AXSM](https://www.lighthorse.io/tickers/axsm) — Axsome Therapeutics, Inc. - Common Stock
- [EDIT](https://www.lighthorse.io/tickers/edit) — Editas Medicine, Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).